• No results found

Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963–2014)

N/A
N/A
Protected

Academic year: 2020

Share "Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963–2014)"

Copied!
12
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 Incidence of end-stage kidney disease to PKD from1970 to 2010 (incidence rates expressed per million populationper year, 95% confidence interval [CI])
Fig. 1 Changes in the age of onset of end-stage kidney disease due to PKD.age of onset according to the time period; for both PKD and non-PKD groups the age of incidence varies significantly over time ( a Median age of onset over the duration of the study (1963–2014); b MedianP < 0.001); c Incidence ofESKD due to PKD according to age group; d Incidence of ESKD due to non-PKD according to age group; e Absolute numbers of PKD patients, accordingto age group, receiving RRT over the study period; f Percentage of PKD patients according to age, over the study period
Fig. 2 Changes in the relative proportions initial RRT modality in non-PKD and PKD patients according to the time-period
Fig. 3 ain non-PKD patients;d Cumulative incidence of time to first transplant over the five study periods in PKD patients; b Cumulative incidence of time to first transplant c Proportion of PKD patients receiving a living donor or deceased donor kidney at
+6

References

Related documents

of his can be explained by his quote that “unquestionably, Democratic political fervor produced a reign of terror among the state’s black population during the summer and fall

FastFourierFit takes four arguments: the first one is the periodic function or, in gen- eral, the list of data points which we want to fit; the second argument is the period L of

It was based on this premise that the study highlighted the socio-economic characteristics of farmers affected by 2010 flood disaster, the quantity of food

The novel AD therapeutic candidate PTI-125 binds and reverses the altered FLNA conformation to prevent Aβ’s signaling via α7nAChR and aberrant activation of TLR4, thus

Piyush et al AbdulHamed,et.al Lakshmi, et.al Shubhangi, et.al Dasofunjo, et.al KHarikumar,et.al T.H.Ngoc, et.al Ak khanna, et.al Partha Ray, et.al Badialyoussi,et.al K.Kumari,

The Ministry of Higher Education of Fundamental Research Grant Scheme has supported this study (Malaysia; Grant code: FGRS/1/2015/ICT04/UKM/02/3). Sarkar et al.,